PBYI
PUMA BIOTECHNOLOGY, INC.
Overview
Puma Biotechnology develops and commercializes cancer treatments, including NERLYNX (neratinib), an oral medication for HER2-positive breast cancer approved in the U.S. and over 40 countries.
PUMA BIOTECHNOLOGY, INC is a Healthcare company operating in Biotechnology with a $405.7M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-082 Q&A exchanges
- Q4 FY2025Earnings2026-02-261 Q&A exchange
- Q3 FY2025Earnings2025-11-072 Q&A exchanges
- Q2 FY2025Earnings2025-08-072 Q&A exchanges
- Q1 FY2025Earnings2025-05-094 Q&A exchanges
- Q4 FY2024Earnings2025-02-2711 Q&A exchanges
- Q3 FY2024Earnings2024-11-079 Q&A exchanges
- Q2 FY2024Earnings2024-08-018 Q&A exchanges
- Q1 FY2024Earnings2024-05-026 Q&A exchanges
- Q4 FY2023Earnings2024-02-295 Q&A exchanges
- Q3 FY2023Earnings2023-11-0211 Q&A exchanges
- Q2 FY2023Earnings2023-08-0312 Q&A exchanges
- Q1 FY2023Earnings2023-05-0417 Q&A exchanges
- Q4 FY2022Earnings2023-03-028 Q&A exchanges
- Q3 FY2022Earnings2022-11-069 Q&A exchanges
- Q2 FY2022Earnings2022-08-075 Q&A exchanges
- Q1 FY2022Earnings2022-05-0513 Q&A exchanges
- Q4 FY2021Earnings2022-03-0316 Q&A exchanges
- Q3 FY2021Earnings2021-11-0413 Q&A exchanges
- Q2 FY2021Earnings2021-08-0511 Q&A exchanges
- Q1 FY2021Earnings2021-05-069 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $0.08—Rev— vs ——EODHD
- Q1 FY20262026-04-29EPS$-0.04 vs $0.04-100.0%Rev$44.8M vs ——EODHD
- Q4 FY20252026-02-25EPS$0.29 vs $0.27+7.4%Rev$75.5M vs ——EODHD
- Q3 FY20252025-11-05EPS$0.21 vs $0.16+31.3%Rev$54.5M vs ——EODHD
- Q2 FY20252025-08-06EPS$0.12 vs $0.09+33.3%Rev$52.4M vs ——EODHD
- Q1 FY20252025-04-29EPS$0.10 vs $-0.22+100.0%Rev$46.0M vs ——EODHD
- Q4 FY20242025-02-25EPS$0.43 vs $0.14+100.0%Rev$59.1M vs ——EODHD
- Q3 FY20242024-11-06EPS$0.41 vs $0.35+17.1%Rev$80.5M vs ——EODHD
- Q2 FY20242024-07-31EPS$-0.09 vs $-0.13+30.8%Rev$47.1M vs ——EODHD
- Q1 FY20242024-05-01EPS$-0.10 vs $-0.22+54.5%Rev$43.8M vs ——EODHD
- Q4 FY20232024-02-28EPS$0.26 vs $0.30-13.3%Rev$72.2M vs ——EODHD
- Q3 FY20232023-11-01EPS$0.12 vs $0.08+50.0%Rev$56.1M vs ——EODHD
- Q2 FY20232023-08-02EPS$0.05 vs $0.01+100.0%Rev$54.6M vs ——EODHD
- Q1 FY20232023-05-03EPS$0.03 vs $-0.07+100.0%Rev$52.8M vs ——EODHD
- Q4 FY20222023-03-01EPS$-0.12 vs $0.01-100.0%Rev$65.7M vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.01 vs $-0.05+80.0%Rev$57.1M vs ——EODHD
- Q2 FY20222022-08-03EPS$0.21 vs $0.01+100.0%Rev$59.5M vs ——EODHD
- Q1 FY20222022-05-04EPS$-0.08 vs $-0.17+52.9%Rev$45.7M vs ——EODHD
- Q4 FY20212022-03-02EPS$0.10 vs $-0.09+100.0%Rev$55.4M vs ——EODHD
- Q3 FY20212021-11-03EPS$-0.90 vs $-0.31-100.0%Rev$46.2M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $0.08 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $-0.04 | $0.04 | -100.0% | $44.8M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $0.29 | $0.27 | +7.4% | $75.5M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $0.21 | $0.16 | +31.3% | $54.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $0.12 | $0.09 | +33.3% | $52.4M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $0.10 | $-0.22 | +100.0% | $46.0M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $0.43 | $0.14 | +100.0% | $59.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $0.41 | $0.35 | +17.1% | $80.5M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.09 | $-0.13 | +30.8% | $47.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.10 | $-0.22 | +54.5% | $43.8M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $0.26 | $0.30 | -13.3% | $72.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $0.12 | $0.08 | +50.0% | $56.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $0.05 | $0.01 | +100.0% | $54.6M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $0.03 | $-0.07 | +100.0% | $52.8M | — | — | EODHD |
| Q4 FY2022 | 2023-03-01 | $-0.12 | $0.01 | -100.0% | $65.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.01 | $-0.05 | +80.0% | $57.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.21 | $0.01 | +100.0% | $59.5M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.08 | $-0.17 | +52.9% | $45.7M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $0.10 | $-0.09 | +100.0% | $55.4M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.90 | $-0.31 | -100.0% | $46.2M | — | — | EODHD |
Source: EODHD. PBYI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks PBYI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 5 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.81 | $0.73 | +11.6% | -2.8% | -2.2% |
| Q4 FY2026 | $0.82 | $0.77 | +6.6% | +1.6% | +3.9% |
| Q3 FY2026 | $0.73 | $0.72 | +1.3% | +7.2% | +9.0% |
| Q2 FY2026 | $0.78 | $0.68 | +15.0% | +4.1% | +3.3% |
| Q1 FY2025 | $0.86 | $0.76 | +13.5% | +0.6% | +0.2% |
| Q4 FY2025 | $0.80 | $0.71 | +12.2% | +1.7% | +2.2% |
| Q3 FY2025 | $0.82 | $0.76 | +8.5% | -0.1% | +2.7% |
| Q2 FY2025 | $0.96 | $0.86 | +11.6% | -4.2% | -3.9% |
| Q1 FY2024 | $0.78 | $0.73 | +6.8% | -1.4% | -0.4% |
| Q4 FY2024 | $0.81 | $0.75 | +8.4% | -0.4% | -0.8% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Maintained2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Alan H AuerbachCEO1 yr 11 mo21 callsCurrentSample
CEO since 2024 • 5/8 beats (63%) • last guidance cut Q2 FY2026
- Maximo F NouguesCFO1 yr 11 mo21 callsCurrentSample
CFO since 2024 • 5/8 beats (63%) • guidance suspended Q1 FY2026
- Douglas M HuntSee Remarks1 yr 11 mono recorded callsCurrentSample
OTHER since 2024 • 7/8 beats (88%) • last call held guidance Q1 FY2026
- Jeffrey Jerome LudwigChief Commercial Officer7 mono recorded callsFormerSample
OTHER_C_SUITE since 2024 • 5/8 beats (63%) • last call held guidance Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PBYI.
$ curl https://api.spokenalpha.com/v1/companies/PBYIFAQ
Frequently asked about PBYI
Where can I find PUMA BIOTECHNOLOGY, INC.'s (PBYI) earnings call transcripts?
Spoken Alpha indexes PBYI's earnings call transcripts at https://spokenalpha.com/companies/PBYI. Each call links to attributed speakers and parsed analyst Q&A.
When was PUMA BIOTECHNOLOGY, INC.'s most recent earnings call?
PUMA BIOTECHNOLOGY, INC. (PBYI) held its most recent earnings call on 2026-05-08, covering fiscal Q1 2026.
What sector is PBYI in?
PUMA BIOTECHNOLOGY, INC. (PBYI) operates in the Healthcare sector (Biotechnology industry).